PXL-330 Platinum device for crosslinking with Peschke riboflavin solution for Keratoconus
Study Summary
This trial will test a new system for corneal cross-linking, a treatment for ectatic disorders. The goal is to see if it is safe and effective.
- Pellucid Marginal Corneal Degeneration
- Keratoconus
- Corneal Ectasia
Treatment Effectiveness
Study Objectives
2 Primary · 2 Secondary · Reporting Duration: 1 year
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Pulsed, accelerated
1 of 2
Pusled, accelerated
1 of 2
Experimental Treatment
500 Total Participants · 2 Treatment Groups
Primary Treatment: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
| Missouri | 100.0% |
What site did they apply to?
| Goodman Eye Center | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Why did patients apply to this trial?
- "I have progressive KC in both eyes treated left in 2018 and needing treatment in right after condition worsening. Ideally help can keep me from further issues and help others dealing with my illness."
How many prior treatments have patients received?
| 1 | 100.0% |
Frequently Asked Questions
How many people are included in this research project?
"That is correct, the listing on clinicaltrials.gov does reveal that this trial has an open call for participants. This particular trial was first made public on October 19th, 2019 and had new information posted as recently as August 19th, 2020. They are looking to enroll 500 individuals at a single location." - Anonymous Online Contributor
Has the PXL-330 Platinum device received FDA approval to be used in conjunction with Peschke riboflavin solution?
"The PXL-330 Platinum device for crosslinking with Peschke riboflavin solution is a new medical intervention, and as such has received a score of 2 in terms of safety." - Anonymous Online Contributor
How is the PXL-330 Platinum device most commonly used in conjunction with Peschke riboflavin solution?
"The PXL-330 Platinum device, when used in conjunction with Peschke riboflavin solution, is a popular tool for dietary and nutritional therapies. However, it has also shown therapeutic value for treating vitamin deficiency, joint pain, and other ailments." - Anonymous Online Contributor
Are patients being signed up for this clinical trial right now?
"This clinical trial is currently seeking participants. The trial was first posted on October 19, 2019 and was last updated on August 19, 2020." - Anonymous Online Contributor